Results 131 to 140 of about 21,171,014 (388)

Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies

BMC Health Services Research
Background Few studies have evaluated direct medical or societal costs of haemophilia in the United Kingdom (UK), and how patient characteristics impact future costs is uncertain.
Ione Woollacott, Amit Chhabra, Tom Burke, Jack Brownrigg, Lucy Richardson, Enrico Ferri Grazzi, Jamie O’Hara, Josie Godfrey, Michael Laffan   +8 more
doaj   +1 more source

Health-related quality of life in children with haemophilia in China: a 4-year follow-up prospective cohort study

Health and Quality of Life Outcomes, 2019
Background Health-related quality of life (HRQoL) has been brought up for decades in haemophilia patients. However, no data to date are available about HRQoL in children with haemophilia using long-term follow up data.
Heng Zhang, Jie Huang, Xiaoyan Kong, Gaoxiang Ma, Yongjun Fang   +4 more
doaj   +1 more source

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, Roseline d'Oiron, Amy L. Dunn, Miguel A. Escobar, Carmen Escuriola‐Ettingshausen, Emna Gouider, Annie Harroche, Cedric Hermans, Victor Jimenez‐Yuste, Radoslaw Kaczmarek, Gili Kenet, Liane Khoo, Robert Klamroth, Florian Langer, David Lillicrap, Johnny Mahlangu, Christoph Male, Tadashi Matsushita, Sandrine Meunier, Wolfgang Miesbach, Beatrice Nolan, Johannes Oldenburg, Brian O'Mahony, Margareth Ozelo, Glenn F. Pierce, Gloria Ramos, Michael Recht, Olivia Romero‐Lux, Dawn Rotellini, Rita C. Santoro, Tammuella C. Singleton, Alok Srivastava, Sophie Susen, Kate Talks, Huyen Tran, Leonard A. Valentino, Jerzy Windyga, Renchi Yang, Maria Elisa Mancuso, also on behalf of AICE, AHAD‐AP, AHCDC, ATHN, CLAHT, EHC, French CRH & MHEMO, HTCCNC, NBDF, PEDNET, UKHCDO, WFH   +59 more
wiley   +1 more source

Diagnosis of von Willebrand disease in Argentina: a single institution experience [PDF]

, 2017
von Willebrand disease (VWD) is the most common autosomal bleeding disorder, mostlyinherited as dominant trait. VWD is due to deficiency/abnormality of von Willebrand factor (VWF).
Blanco, Alicia Noemi, Kempfer, Ana Catalina, Lazzari, María Ángela, Paiva Palomino, Juvenal Hernán, Sánchez Luceros, Analía Gabriela, Woods, Adriana Inés   +5 more
core   +1 more source

Health‐Related Quality of Life in Adult Patients With von Willebrand Disease From Germany: Results of the WIL‐QoL Study

Haemophilia, EarlyView.
ABSTRACT Introduction Assessment of health‐related quality of life (HRQoL) is relatively new in von Willebrand disease (VWD). So far, generic questionnaires have mainly been used for HRQoL assessment in VWD. Aims To assess generic and disease‐specific HRQoL in adult VWD patients and compare HRQoL with the general German population.
Sylvia von Mackensen, Carolin Moorthi, Ronald Fischer, Susan Halimeh, Christine Heller, Wolfgang Miesbach, Freimut H. Schilling, Cornelia Wermes, Guenter Auerswald, the WIL‐QoL study group, Karin Beutel, Georg Goldmann, Bettina‐Kemkes Matthes, Robert Klamroth, Ralf Knöfler, Christoph Male, Johannes Oldenburg, Ute Scholz   +17 more
wiley   +1 more source

Advanced therapies for the treatment of hemophilia: future perspectives [PDF]

, 2012
Monogenic diseases are ideal candidates for treatment by the emerging advanced therapies, which are capable of correcting alterations in protein expression that result from genetic mutation.
Gaban, Aline S., Liras, Antonio, Segovia, Cristina   +2 more
core   +4 more sources

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post‐Marketing Study

Haemophilia, EarlyView.
ABSTRACT This is a plain language summary of the results of a trial of damoctocog alfa pegol (BAY 94–9027, Jivi).
Pål André Holme, Lone Hvitfeldt Poulsen, Claudia Tueckmantel, Monika Maas Enriquez, María Teresa Alvarez Román, Raimondo De Cristofaro   +5 more
wiley   +1 more source

Acquired Hemophilia Caused by Ureteral Tumor [PDF]

, 2018
K
Berczi, Csaba, Boda, Zoltán, Flaskó, Tibor, Molnárné Rázsó, Katalin, Osváth, Péter   +4 more
core   +1 more source

The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count [PDF]

, 1998
The data of two cohort studies of HIV-infected individuals were used to examine whether the rate of CD4 decline is a determinant of HIV progression, independent of the most recent CD4 count.
Lee, CA, Lepri, AC, Pezzotti, P, Phillips, AN, Rezza, G, Sabin, CA   +5 more
core   +1 more source

PERAWATAN GIGI DAN MULUT PENDERITA HEMOFILIA

Journal of Dentistry Indonesia, 2015
Haemophilia is a congenital haemorrhagic disorders passed down by the x linked recessive, divided into two: Haemophilia A caused by deficiency of factor VIII and Haemophilia B caused by deficiency of factor IX.
Siti Marhamah
doaj   +1 more source